Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units

MONTREAL--(BUSINESS WIRE)--Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces the launch of a proposed private placement financing of subscription receipts for maximum aggregate gross proceeds of CA$4.0 million (the “Financing”) and that it has received a CA$2.5 million lead order from an institutional investor in connection with the Financing. Each subscription receipt will entitle the holder thereof, upon satisfaction of the Escrow Release Conditions (as defined below),.

Business Wire • Oct 15, 2026

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why

PRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.

Zacks Investment Research • Oct 12, 2026

Leading Indicators For The October Breakout Cycle

Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of the S&P 500's annual returns with more positive years than all the other quarters. Small cap healthcare/biotech, technology, and consumer cyclicals—like PRME, CRNC, and FOSL—are highlighted as early breakout candidates with strong institutional interest and analyst targets.

Seeking Alpha • Oct 11, 2026

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most prevalent Wilson disease-causing mutation in North America and Europe‌ --

GlobeNewsWire • Oct 5, 2026

Prime Medicine Gets FDA Green Light for Gene Editing Study

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology firm developing one-time curative genetic therapies, announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for PM647.

Benzinga • Sep 25, 2026

Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement

Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. PM359 is positioned for a potential BLA submission for CGD in 1H 2027, leveraging RMAT and other regulatory designations. Initial clinical data from global phase 1/2 studies of PM577a [WD] and PM647 [AATD] are expected in 2027, targeting significant market opportunities.

Seeking Alpha • Sep 25, 2026

Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Tamboran Resources Corp. (NYSE:TBN) to post a quarterly loss of 30 cents per share on revenue of $3.82 million before the opening bell, according to data from Benzinga Pro. Tamboran Resources shares gained 1.4% to close at $36.25 on Thursday.

Benzinga • Sep 25, 2026

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

-- Clearance highlights continued execution, modularity and momentum across Prime Medicine's liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected in 2027 --

GlobeNewsWire • Sep 24, 2026

Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout

Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.

Investors Business Daily • Sep 17, 2026

Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026